Search results for "Cardiovascular Disease"
MKSAP Quiz: Establish care visit for pediatric cancer survivor
A 28-year-old woman is seen to establish care. Medical history is significant for acute lymphoblastic leukemia diagnosed and treated at age 5 years; she has been leukemia free since completion of therapy. Following a physical exam and cervical cancer screening, what is the most appropriate additional survivorship assessment to perform next?
https://immattersacp.org/weekly/archives/2022/02/22/3.htm
22 Feb 2022
Meta-analysis compares mortality benefits of heart failure treatment combinations
Patients taking an angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter-2 inhibitor showed the greatest reduction in risk of death, the analysis of heart failure with reduced ejection fraction found.
https://immattersacp.org/weekly/archives/2021/12/14/4.htm
14 Dec 2021
MKSAP Quiz: Perioperative evaluation for hip arthroplasty
A 52-year-old woman undergoes perioperative evaluation. She has osteoarthritis of the right hip since sustaining injuries in a motor vehicle accident 15 years ago and is scheduled for elective hip arthroplasty in the next few months. Following a physical exam and lab studies, what is the most appropriate test to perform next?
https://immattersacp.org/weekly/archives/2020/02/11/3.htm
11 Feb 2020
Racial, economic disparities found in use of SGLT-2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
https://immattersacp.org/weekly/archives/2021/04/20/2.htm
20 Apr 2021
MKSAP Quiz: Routine follow-up appointment with schizophrenia
A 56-year-old man is evaluated during a routine follow-up appointment. He has schizophrenia treated with olanzapine. Currently, the patient experiences no hallucinations or delusions. He is otherwise healthy. Following a physical exam, what should also be monitored in this patient?
https://immattersacp.org/weekly/archives/2021/10/26/3.htm
26 Oct 2021
New reports on early symptoms, cardiac complications of COVID-19
Loss of smell and taste have been suggested as possible early symptoms of COVID-19, and cardiac complications appear to be a significant issue among infected patients with or without baseline cardiovascular disease.
https://immattersacp.org/weekly/archives/2020/03/31/2.htm
31 Mar 2020
MKSAP Quiz: Follow-up for stable chronic kidney disease
A 57-year-old man is evaluated during follow-up for stable chronic kidney disease diagnosed 1 year ago. He also has type 2 diabetes mellitus, hyperlipidemia, and peripheral artery disease. On physical examination, blood pressure is 128/74 mm Hg, pulse rate is 65/min, and respiration rate is 18/min. Bilateral carotid and lower abdominal quadrant bruits are heard. Peripheral extremity pulses are diminished. The remainder of the examination is normal. After laboratory studies, what is the appropriate management?
https://immattersacp.org/weekly/archives/2021/11/09/3.htm
9 Nov 2021
Cardiovascular safety of febuxostat and allopurinol compared in patients with gout and CVD
In a modified intention-to-treat analysis, the primary end point of first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization for unstable angina occurred in 10.8% of patients taking febuxostat and in 10.4% of patients taking allopurinol (hazard ratio, 1.03).
https://immattersacp.org/weekly/archives/2018/03/20/4.htm
20 Mar 2018
Vitamin D did not lower fracture risk in generally healthy patients, study finds
A new analysis of a large trial found no difference in total fractures, nonvertebral fractures, or hip fractures by whether men 50 years of age or older and women 55 years of age or older were randomized to vitamin D or placebo.
https://immattersacp.org/weekly/archives/2022/08/02/1.htm
2 Aug 2022
Latest COVID-19 guidelines come out against bamlanivimab, remdesivir
The NIH and the Infectious Diseases Society of America found insufficient data to support bamlanivimab, while the World Health Organization said the same about remdesivir. The FDA issued more emergency use authorizations, and research looked at racial and other disparities in COVID-19 outcomes.
https://immattersacp.org/weekly/archives/2020/11/24/1.htm
24 Nov 2020